A Study of Population Pharmacokinetics of Docetaxel (Taxotere) in Caucasian and African-American Cancer Patients
A Study of Population Pharmacokinetics of Docetaxel (Taxotere) in Caucasian and African-American Cancer Patients
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
PURPOSE: Phase II trial to compare the effectiveness of docetaxel in treating Caucasian and African American patients who have solid tumors.
OBJECTIVES:
OUTLINE: Patients receive docetaxel IV over 1 hour on day 1. Patients may receive additional courses beginning 21 days after the first docetaxel dose at the discretion of the physician.
DISEASE CHARACTERISTICS:
PATIENT CHARACTERISTICS:
Age:
Performance status:
Hematopoietic:
Hepatic:
Renal:
Other:
PRIOR CONCURRENT THERAPY:
Biologic therapy:
Chemotherapy:
Endocrine therapy:
Radiotherapy:
Surgery:
Other:
At least 48 hours since prior or concurrent ethanol (CYP3A enzyme inducer) or grapefruit juice (CYP3A enzyme inhibitor)
At least 7 days since prior or concurrent CYP450 inducing drugs:
At least 7 days since prior or concurrent CYP450 3A inhibiting drugs:
Washington D.C., District of Columbia 20422, United States
West Palm Beach, Florida 33401, United States
Fort Wayne, Indiana 46885-5099, United States
Baltimore, Maryland 21201, United States
Boston, Massachusetts 02115, United States
Worcester, Massachusetts 01655, United States
Syracuse, New York 13217, United States
Winston-Salem, North Carolina 27157-1082, United States
White River Junction, Vermont 05009, United States
Roanoke, Virginia 24014, United States